The Role of Circulating Tumor DNA (ctDNA) in Colorectal Cancer Screening and Management

Detecting colorectal cancer (CRC) early can significantly change a patient’s prognosis. While traditional screening methods remain the gold standard, a non-invasive strategy is gaining momentum: blood-based circulating tumor DNA (ctDNA) assays. By analyzing fragments of tumor DNA circulating in the bloodstream, clinicians are finding new ways to screen at-risk populations, predict recurrence, and tailor treatment plans with greater precision.

What is ctDNA and How Does it Function in CRC?

Circulating tumor DNA (ctDNA) consists of tiny fragments of DNA shed by tumor cells into the bloodstream. Because these fragments carry the specific mutations of the cancer, they act as a “liquid biopsy.” In colorectal cancer, ctDNA assays are used to identify genetic markers that facilitate doctors understand the nature of the tumor without needing an invasive tissue biopsy every time.

Clinical Applications of ctDNA

The utility of ctDNA varies depending on the stage of the disease and the clinical goal. According to ASCO publications, ctDNA is currently applied in three primary ways:

• Screening: Serving as a non-invasive tool for CRC detection in populations at high risk.
• Treatment Selection: Identifying actionable biomarkers to guide first-line treatment for patients with metastatic CRC.
• MRD Detection: Identifying molecular residual disease (MRD) in early-stage CRC to determine if cancer remains after surgery.

Predicting Recurrence and Survival

One of the most critical uses of ctDNA is its ability to predict whether a patient will experience a relapse. Data from a systematic review and meta-analysis of 65 cohort studies indicates a significant association between ctDNA presence and shorter relapse-free survival (RFS) and overall survival (OS) across all types of CRC patients, particularly after completing recommended guideline treatments (Journal of the National Cancer Center).

The GALAXY Study Findings

The CIRCULATE-Japan GALAXY observational study, which included 2,240 patients with stage II–III colon cancer or stage IV CRC, highlighted the profound prognostic value of ctDNA. The study found that ctDNA positivity during the MRD window was linked to:

• Inferior Disease-Free Survival (DFS): A hazard ratio (HR) of 11.99.
• Inferior Overall Survival (OS): A hazard ratio (HR) of 9.68.

for patients who did experience a recurrence, those who were ctDNA-positive had significantly shorter overall survival (HR: 2.71), as detailed in research published by Nature.

Guiding Adjuvant Therapy

The decision to apply adjuvant chemotherapy (ACT) in stage II colon cancer is often debated. CtDNA provides a potential solution to this uncertainty. The presence of ctDNA after surgery is a strong predictor of incredibly poor recurrence-free survival (New England Journal of Medicine).

Monitoring how a patient responds to chemotherapy through ctDNA levels also provides critical insights. The GALAXY study noted a stark difference in outcomes based on ctDNA clearance:

• Sustained Clearance: Associated with a 24-month DFS of 89.0% and a 24-month OS of 100.0%.
• Transient Clearance: Associated with a 24-month DFS of only 3.3% and a 24-month OS of 82.3%.

Notably, the true spontaneous clearance rate—where ctDNA disappeared and no clinical recurrence occurred—was very low at 1.9%.

Comparing ctDNA to Traditional Imaging

While CT scans and MRIs are standard for monitoring cancer, they rely on the tumor reaching a certain size to be visible. CtDNA assays may detect recurrence earlier than radiographic progression, allowing clinicians to intervene sooner (Journal of the National Cancer Center).

Frequently Asked Questions

Can ctDNA replace a colonoscopy?

Currently, ctDNA is explored as a screening tool for at-risk populations and a way to monitor disease, but it is generally used to complement existing diagnostic and screening protocols rather than replace them entirely.

What is “Molecular Residual Disease” (MRD)?

MRD refers to the small number of cancer cells that remain in the body after treatment (such as surgery) that are too few to be detected by traditional imaging but can be found using highly sensitive tests like ctDNA assays.

How does ctDNA help in Stage II colon cancer?

In Stage II, where the benefit of chemotherapy is debated, ctDNA can help identify patients at high risk of recurrence who are most likely to benefit from adjuvant therapy.

The Future of CRC Monitoring

The shift toward “liquid biopsies” represents a move toward more personalized oncology. By integrating ctDNA monitoring into the standard of care, physicians can better stratify mortality risk and refine the use of adjuvant therapies, ensuring that patients receive the right treatment at the right time.